BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 37959208)

  • 1. The Role of Pharmacogenetics in the Therapeutic Response to Thiopurines in the Treatment of Inflammatory Bowel Disease: A Systematic Review.
    Ribeiro AC; Gerheim PSAS; Chebli JMF; Nascimento JWL; de Faria Pinto P
    J Clin Med; 2023 Oct; 12(21):. PubMed ID: 37959208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing.
    Teml A; Schaeffeler E; Herrlinger KR; Klotz U; Schwab M
    Clin Pharmacokinet; 2007; 46(3):187-208. PubMed ID: 17328579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease.
    Chouchana L; Narjoz C; Beaune P; Loriot MA; Roblin X
    Aliment Pharmacol Ther; 2012 Jan; 35(1):15-36. PubMed ID: 22050052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thiopurine metabolites variations during co-treatment with aminosalicylates for inflammatory bowel disease: effect of N-acetyl transferase polymorphisms.
    Stocco G; Cuzzoni E; De Iudicibus S; Favretto D; Malusà N; Martelossi S; Pozzi E; Lionetti P; Ventura A; Decorti G
    World J Gastroenterol; 2015 Mar; 21(12):3571-8. PubMed ID: 25834322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond TPMT: genetic influences on thiopurine drug responses in inflammatory bowel disease.
    Roberts RL; Gearry RB; Kennedy MA; Barclay ML
    Per Med; 2008 May; 5(3):233-248. PubMed ID: 29783500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
    Gearry RB; Barclay ML
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thiopurine S-methyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease and autoimmune disorders: influence on treatment response.
    Abaji R; Krajinovic M
    Pharmgenomics Pers Med; 2017; 10():143-156. PubMed ID: 28507448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing thiopurine therapy in children with acute lymphoblastic leukemia: A promising "MINT" sequencing strategy and therapeutic "DNA-TG" monitoring.
    Guo HL; Zhao YT; Wang WJ; Dong N; Hu YH; Zhang YY; Chen F; Zhou L; Li T
    Front Pharmacol; 2022; 13():941182. PubMed ID: 36238550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Frequency of serious adverse events of thiopurine treatment in normal thiopurine S-methyltransferase genotype children with inflammatory bowel disease].
    Tárnok A
    Orv Hetil; 2019 Feb; 160(5):179-185. PubMed ID: 30686035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liquid chromatography-tandem mass spectrometry analysis of erythrocyte thiopurine nucleotides and effect of thiopurine methyltransferase gene variants on these metabolites in patients receiving azathioprine/6-mercaptopurine therapy.
    Dervieux T; Meyer G; Barham R; Matsutani M; Barry M; Boulieu R; Neri B; Seidman E
    Clin Chem; 2005 Nov; 51(11):2074-84. PubMed ID: 16166171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease.
    Coenen MJ; de Jong DJ; van Marrewijk CJ; Derijks LJ; Vermeulen SH; Wong DR; Klungel OH; Verbeek AL; Hooymans PM; Peters WH; te Morsche RH; Newman WG; Scheffer H; Guchelaar HJ; Franke B;
    Gastroenterology; 2015 Oct; 149(4):907-17.e7. PubMed ID: 26072396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations.
    Haglund S; Taipalensuu J; Peterson C; Almer S
    Br J Clin Pharmacol; 2008 Jan; 65(1):69-77. PubMed ID: 17662091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy.
    Gilissen LP; Wong DR; Engels LG; Bierau J; Bakker JA; Paulussen AD; Romberg-Camps MJ; Stronkhorst A; Bus P; Bos LP; Hooymans PM; Stockbrügger RW; Neef C; Masclee AA
    J Crohns Colitis; 2012 Jul; 6(6):698-707. PubMed ID: 22398098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thiopurine Therapy in Patients With Inflammatory Bowel Disease: A Focus on Metabolism and Pharmacogenetics.
    Chang JY; Cheon JH
    Dig Dis Sci; 2019 Sep; 64(9):2395-2403. PubMed ID: 31290039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice.
    Gearry RB; Barclay ML; Roberts RL; Harraway J; Zhang M; Pike LS; George PM; Florkowski CM
    Intern Med J; 2005 Oct; 35(10):580-5. PubMed ID: 16207256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of thiopurine testing in the management of inflammatory bowel diseases in clinical practice: a worldwide survey of experts.
    Roblin X; Oussalah A; Chevaux JB; Sparrow M; Peyrin-Biroulet L
    Inflamm Bowel Dis; 2011 Dec; 17(12):2480-7. PubMed ID: 21351210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
    Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
    J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxanthine guanine phosphoribosyltransferase activity is related to 6-thioguanine nucleotide concentrations and thiopurine-induced leukopenia in the treatment of inflammatory bowel disease.
    Ding L; Zhang FB; Liu H; Gao X; Bi HC; Wang XD; Chen BL; Zhang Y; Zhao LZ; Zhong GP; Hu PJ; Chen MH; Huang M
    Inflamm Bowel Dis; 2012 Jan; 18(1):63-73. PubMed ID: 21381155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review with meta-analysis: risk factors for thiopurine-induced leukopenia in IBD.
    van Gennep S; Konté K; Meijer B; Heymans MW; D'Haens GR; Löwenberg M; de Boer NKH
    Aliment Pharmacol Ther; 2019 Sep; 50(5):484-506. PubMed ID: 31342537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics of thiopurines for inflammatory bowel disease in East Asia: prospects for clinical application of NUDT15 genotyping.
    Kakuta Y; Kinouchi Y; Shimosegawa T
    J Gastroenterol; 2018 Feb; 53(2):172-180. PubMed ID: 29192347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.